Individualization of thiopurine therapy: Thiopurine S-methyltransferase and beyond

Pharmacogenomics

Volumn 10, Issue 8, 2009, Pages 1309-1322

  Karas Kuzelicki, Natasa ^a   Mlinaric Rascan, Irena ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

5,10 methylene tetrahydrofolate reductase; Cancer pharmacogenomics; Folates; Homocysteine; S adenosylmethionine; Thiopurine S methyltransferase; Thiopurines; Thymidylate synthase

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; AZATHIOPRINE; MERCAPTOPURINE; METHIONINE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); S ADENOSYLMETHIONINE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD TOXICITY; DEPRESSION; DNA METHYLATION; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME ACTIVITY; EXON; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; INFECTION; LIVER DISEASE; OSTEOARTHRITIS; PHARMACOGENETICS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; TREATMENT DURATION;

6-MERCAPTOPURINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; METABOLIC DETOXICATION, DRUG; METHYLTRANSFERASES; PHARMACOGENETICS; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 70649097090     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.78     Document Type: Review

References (87)

1. Gurwitz D, McLeod HL: Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics 8, 311-314 (2007). (Pubitemid 46585494)
2. Gurwitz D, Motulsky AG: 'Drug reactions, enzymes, and biochemical genetics': 50 years later. Pharmacogenomics 8, 1479-1484 (2007). (Pubitemid 350286392)
3. Marsh S, van Booven DJ: The increasing complexity of mercaptopurine pharmacogenomics. Clin. Pharmacol. Ther. 85, 139-141 (2009).
4. Sanderson J, Ansari A, Marinaki T, Duley J: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann. Clin. Biochem. 41, 294-302 (2004). (Pubitemid 38954878)
5. Pui CH, Campana D, Evans WE: Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol. 2, 597-607 (2001). (Pubitemid 32998539)
6. Pui CH, Evans WE: Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605-615 (1998).
7. Hartford C, Vasquez E, Schwab M et al.: Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res. 67, 4965-4972 (2007). ■ First description of TPMT knockout animal model. (Pubitemid 46910205)
8. Evans WE: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug Monit. 26, 186-191 (2004).
9. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14, 567-572 (2000).
10. Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M: Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2-*24). Pharmacogenet. Genomics 18, 887-893 (2008).
11. Collie-Duguid ES, Pritchard SC, Powrie RH et al.: The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9, 37-42 (1999).
12. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE: Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. 8, 371-376 (1999).
13. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE: Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad. Sci. USA 94, 6444-6449 (1997). (Pubitemid 27270704)
14. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM: Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl Acad. Sci. USA 102, 9394-9399 (2005). (Pubitemid 40923574)
15. Roberts RL, Gearry RB, Bland MV et al.: Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet. Genomics 18, 434-438 (2008).
16. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91, 2001-2008 (1999).
17. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I: Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 23(5), 971-974 (2008). ■■ First report showing synergistic effect of TPMT and MTHFR genotype on 6-mercaptopurine (6-MP) toxicity in patients with childhood acute lymphoblastic leukemia.
18. McLeod HL, Coulthard S, Thomas AE et al.: Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 105, 696-700 (1999). (Pubitemid 29277028)
19. Stanulla M, Schaeffeler E, Flohr T et al.: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293, 1485-1489 (2005). (Pubitemid 40393293)
20. Alves S, Amorim A, Ferreira F, Prata MJ: Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin. Pharmacol. Ther. 70, 165-174 (2001). (Pubitemid 32777769)
21. Ford L, Kampanis P, Berg J: Thiopurine S-methyltransferase genotype-phenotype concordance: used as a quality assurance tool to help control the phenotype assay. Ann. Clin. Biochem. 46(Pt 2), 152-154 (2009).
22. Indjova D, Atanasova S, Shipkova M, Armstrong VW, Oellerich M, Svinarov D: Phenotypic and genotypic analysis of thiopurine S-methyltransferase polymorphism in the Bulgarian population. Ther. Drug Monit. 25, 631-636 (2003). (Pubitemid 37238898)
23. Larovere LE, de Kremer RD, Lambooy LH, De Abreu RA: Genetic polymorphism of thiopurine S-methyltransferase in Argentina. Ann. Clin. Biochem. 40, 388-393 (2003).
24. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J: Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin. Pharmacol. Ther. 70, 183-188 (2001). (Pubitemid 32777771)
25. Milek M, Murn J, Jaksic Z, Lukac Bajalo J, Jazbec J, Mlinaric Rascan I: Thiopurine S-methyltransferase pharmacogenetics: genotype to phenotype correlation in the Slovenian population. Pharmacology 77, 105-114 (2006). (Pubitemid 44114386)
26. Otterness D, Szumlanski C, Lennard L et al.: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62, 60-73 (1997). (Pubitemid 27327100)
27. Reis M, Santoro A, Suarez-Kurtz G: Thiopurine methyltransferase phenotypes and genotypes in Brazilians. Pharmacogenetics 13, 371-373 (2003). (Pubitemid 36724531)
28. Rossi AM, Bianchi M, Guarnieri C, Barale R, Pacifici GM: Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur. J. Clin. Pharmacol. 57, 51-54 (2001). (Pubitemid 32391413)
29. Schaeffeler E, Fischer C, Brockmeier D et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407-417 (2004). ■■ TPMT genotype-to-phenotype analysis in a large (n = 1214) population and a good review of similar studies in other populations. (Pubitemid 38971231)
30. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B et al.: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J. Pharmacol. 125, 879-887 (1998). (Pubitemid 28482633)
31. Yates CR, Krynetski EY, Loennechen T et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-614 (1997). (Pubitemid 27172187)
32. Scheuermann TH, Keeler C, Hodsdon ME: Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone. Biochemistry 43, 12198-12209 (2004). ■■ First report describing stabilization of TPMT protein by S-adenosylmethionine (SAM) analog. (Pubitemid 39280563)
33. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG: Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J. Hepatol. 37, 441-447 (2002).
34. Evans WE, Hon YY, Bomgaars L et al.: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 19, 2293-2301 (2001). (Pubitemid 32366982)
35. Ansari A, Aslam Z, De Sica A et al.: Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol. Ther. 28, 749-757 (2008).
36. Stocco G, Cheok MH, Crews KR et al.: Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85, 164-172 (2009).
37. Jones TS, Yang W, Evans WE, Relling MV: Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin. Pharmacol. Ther. 81, 729-734 (2007). ■ Genome-wide approach analysis to asses predictors of TPMT activity. (Pubitemid 46625112)
38. Panayiotidis MI, Stabler SP, Allen RH, Ahmad A, White CW: Cigarette smoke extract increases S-adenosylmethionine and cystathionine in human lung epithelial-like (A549) cells. Chem. Biol. Interact. 147, 87-97 (2004). (Pubitemid 38081271)
39. Mosharov E, Cranford MR, Banerjee R: The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry 39, 13005-13011 (2000). (Pubitemid 30825904)
40. Milek M, Karas Kuzelicki N, Smid A, Mlinaric-Rascan I: S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts. Biochem. Pharmacol. 77(12), 1845-1853 (2009).
41. Bottiglieri T: S-Adenosyl-L-methionine (SAMe): from the bench to the bedside - molecular basis of a pleiotrophic molecule. Am. J. Clin. Nutr. 76, 1151S-1157S (2002).
42. Grillo MA, Colombatto S: S-adenosylmethionine and its products. Amino Acids 34, 187-193 (2008).
43. Lu SC, Alvarez L, Huang ZZ et al.: Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc. Natl Acad. Sci. USA 98, 5560-5565 (2001). (Pubitemid 32435681)
44. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA et al.: Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 16, 1292-1294 (2002).
45. Arenas M, Simpson G, Lewis CM et al.: Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin. Chem. 51, 2371-2374 (2005). ■■ First report of MTHFR genotype modilating TPMT activity in healthy individuals. (Pubitemid 41692587)
46. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH: Homocysteine, folate, methylation, and monoamine metabolism in depression. J. Neurol. Neurosurg. Psychiatry 69, 228-232 (2000). (Pubitemid 30466029)
47. Reed MC, Nijhout HF, Sparks R, Ulrich CM: A mathematical model of the methionine cycle. J. Theor. Biol. 226, 33-43 (2004). (Pubitemid 37445207)
48. Kager L, Cheok M, Yang W et al.: Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J. Clin. Invest. 115, 110-117 (2005). (Pubitemid 40385511)
49. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH: Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am. J. Med. Genet. 108, 1-6 (2002). (Pubitemid 34101374)
50. Chen Z, Karaplis AC, Ackerman SL et al.: Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 10, 433-443 (2001). ■ Study demonstrating the decreased SAM levels in MTHFR knockout mice. (Pubitemid 32181666)
51. Botto LD, Yang Q: 5,10-methylene tetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am. J. Epidemiol. 151, 862-877 (2000).
52. Ogino S, Wilson RB: Genotype and haplotype distributions of MTHFR 677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J. Hum. Genet. 48, 1-7 (2003). (Pubitemid 36205639)
53. Isotalo PA, Wells GA, Donnelly JG: Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am. J. Hum. Genet. 67, 986-990 (2000).
54. van der Put NM, Gabreels F, Stevens EM et al.: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 62, 1044-1051 (1998). (Pubitemid 28199004)
55. Chocair PR, Duley JA, Sabbaga E, Arap S, Simmonds HA, Cameron JS: Fast and slow methylators: do racial differences influence risk of allograft rejection? Q. J. Med. 86, 359-363 (1993). (Pubitemid 23197325)
56. Nishio K, Goto Y, Kondo T et al.: Serum folate and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism adjusted for folate intake. J. Epidemiol. 18, 125-131 (2008).
57. Bagley PJ, Selhub J: A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl Acad. Sci. USA 95, 13217-13220 (1998).
58. Friso S, Choi SW, Girelli D et al.: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl Acad. Sci. USA 99, 5606-5611 (2002). (Pubitemid 34411596)
59. Jacques PF, Bostom AG, Williams RR et al.: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7-9 (1996).
60. Chiang EP, Wang YC, Tang FY: Folate restriction and methylenetetrahydrofolate reductase 677T polymorphism decreases adoMet synthesis via folate-dependent remethylation in human-transformed lymphoblasts. Leukemia 21, 651-658 (2007).
61. Kaneda S, Nalbantoglu J, Takeishi K et al.: Structural and functional analysis of the human thymidylate synthase gene. J. Biol. Chem. 265, 20277-20284 (1990). (Pubitemid 120014007)
62. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197 (1995).
63. Mandola MV, Stoehlmacher J, Muller-Weeks S et al.: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63, 2898-2904 (2003). (Pubitemid 36667162)
64. Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW: Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum. Genet. 111, 299-302 (2002).
65. Gellekink H, Blom HJ, den Heijer M: Associations of common polymorphisms in the thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4- carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes with folate and homocysteine levels and venous thrombosis risk. Clin. Chem. Lab. Med. 45, 471-476 (2007). (Pubitemid 46632212)
66. Rocha JC, Cheng C, Liu W et al.: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105, 4752-4758 (2005). (Pubitemid 40807300)
67. Krajinovic M, Costea I, Chiasson S: Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359, 1033-1034 (2002). (Pubitemid 34286543)
68. Sadeghian S, Fallahi F, Salarifar M et al.: Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc. Disord. 6, 38 (2006). (Pubitemid 44541833)
69. Hale JP, Lilleyman JS: Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch. Dis. Child. 66, 462-466 (1991).
70. Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddocks JL: Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization. Br. J. Cancer 49, 703-707 (1984). (Pubitemid 14113726)
71. Cooper SC, Ford LT, Berg JD, Lewis MJ: Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics 9, 303-309 (2008).
72. Gisbert JP, Gomollon F, Cara C et al.: Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig. Dis. Sci. 52, 1262-1269 (2007). (Pubitemid 46626159)
73. Klemetsdal B, Straume B, Wist E, Aarbakke J: Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur. J. Clin. Pharmacol. 44, 147-152 (1993). (Pubitemid 23047750)
74. Tamm R, Oselin K, Kallassalu K et al.: Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. Clin. Chem. Lab. Med. 46, 974-979 (2008). (Pubitemid 352000492)
75. Ganiere-Monteil C, Medard Y, Lejus C et al.: Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur. J. Clin. Pharmacol. 60, 89-96 (2004). (Pubitemid 38626437)
76. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J: Determinants of plasma total homocysteine concentration in the Framingham offspring cohort. Am. J. Clin. Nutr. 73, 613-621 (2001). (Pubitemid 32176514)
77. Nygard O, Refsum H, Ueland PM, Vollset SE: Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am. J. Clin. Nutr. 67, 263-270 (1998). (Pubitemid 28076718)
78. Bauer M, Katzenberger JD, Hamm AC et al.: Purine and folate metabolism as a potential target of sex-specific nutrient allocation in Drosophila and its implication for lifespan-reproduction tradeoff. Physiol. Genomics 25, 393-404 (2006). (Pubitemid 43764762)
79. Park EI, Garrow TA: Interaction between dietary methionine and methyl donor intake on rat liver betaine-homocysteine methyltransferase gene expression and organization of the human gene. J. Biol. Chem. 274, 7816-7824 (1999).
80. Schwahn BC, Chen Z, Laryea MD et al.: Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J. 17, 512-514 (2003).
81. Chadwick LH, McCandless SE, Silverman GL, Schwartz S, Westaway D, Nadeau JH: Betaine-homocysteine methyltransferase-2: cDNA cloning, gene sequence, physical mapping, and expression of the human and mouse genes. Genomics 70, 66-73 (2000).
82. Weisberg IS, Park E, Ballman KV et al.: Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis 167, 205-214 (2003). (Pubitemid 36773521)
83. Morin I, Platt R, Weisberg I et al.: Common variant in betaine-homocysteine methyltransferase (BHMT) and risk for spina bifida. Am. J. Med. Genet. A 119A, 172-176 (2003). (Pubitemid 37063888)
84. Chiang PK, Gordon RK, Tal J et al.: S-adenosylmethionine and methylation. FASEB J. 10, 471-480 (1996). (Pubitemid 26120322)
85. Fakhoury M, Andreu-Gallien J, Mahr A et al.: Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? J. Clin. Pharm. Ther. 32, 633-639 (2007). (Pubitemid 350135107)
86. Cannon LM, Butler FN, Wan W, Zhou ZS: A stereospecific colorimetric assay for (S,S)-adenosylmethionine quantification based on thiopurine methyltransferase-catalyzed thiol methylation. Anal. Biochem. 308, 358-363 (2002). (Pubitemid 35177150)
87. Heyduk T, Heyduk E: Molecular beacons for detecting DNA binding proteins. Nat. Biotechnol. 20, 171-176 (2002). (Pubitemid 34158033)